ImmuneOnco Biopharmaceuticals Shanghai 1541.HK · HKD

Its shares trade on HKEX under the ticker 1541.HK. It has been listed since 5 September 2023. In the fiscal year to 31 December 2025, it reported revenue of CN¥150.3m and a net loss of CN¥212.9m. At that date it held total assets of CN¥1.10bn and shareholders' equity of CN¥791.8m.

ImmuneOnco Biopharmaceuticals Shanghai Inc is a CN-based company operating in Biotechnology industry. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2023-09-05. ImmuneOnco Biopharmaceuticals Shanghai Inc is a China-based company mainly engaged in research and development of testing biotechnology. The firm's main businesses include the development of biotechnology for the systemic utilization of innate and adaptive immunity, and the development of next-generation tumor immunotherapies, which primarily focus on the adaptive immune system. The firm mainly operates its businesses in the domestic and overseas markets.

Figures and description from our data supplier, not checked against the company's own report.

• Dr. Wenzhi TianChairman of the Board, Chief Executive Officer, Chief Scientific Officer, since 2022
• Ms. Ziyi SongChief Financial Officer, Executive Director
• Mr. Qiying LuSenior Vice President, Chief Medical Officer
• Mr. Ruliang ZhangVice President - CMC & Clinical Registration
• Mr. Song LiExecutive Director, Senior R&D Director
• Ms. Mei GuanExecutive Director, Secretary of the Board, Joint Company Secretary, since 2022
• Mr. Cong XuNon-Executive Director
• Mr. Tat ChiNon-Executive Independent Director
• Dr. Kendall SmithNon-Executive Independent Director
• Dr. Zhu ZhenpingNon-Executive Independent Director

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.